Insider Trading History of Fust Matthew K

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Fust Matthew K since 2015. This trader's CIK number is 1397266. At the time of last reporting, Fust Matthew K was the Director of Crinetics Pharmaceuticals, Inc.. (stock ticker symbol CRNX). Also see all insider trading activities at Crinetics Pharmaceuticals, Inc..

Note that in the past Fust Matthew K also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Neumora Therapeutics, Inc. (NMRA) by Fust Matthew K

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2024 NMRA 0 $0 21,788 $370,964 21,788 $130,083

Yearly summary of insider trading at Crinetics Pharmaceuticals, Inc. (CRNX) by Fust Matthew K

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2025 CRNX 0 $0 16,000 $716,000 10,000 $19,100
2024 CRNX 0 $0 60,000 $2,643,300 60,000 $1,274,880
2022 CRNX 0 $0 5,700 $119,454 5,700 $8,265
2021 CRNX 0 $0 30,000 $681,500 30,000 $57,299
2019 CRNX 0 $0 3,500 $78,750 3,500 $6,685

Yearly summary of insider trading at Dermira, Inc. (DERM) by Fust Matthew K

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2019 DERM 0 $0 12,000 $133,638 3,000 $0
2018 DERM 0 $0 4,000 $55,000 3,000 $0
2015 DERM 0 $0 0 $0 9,051 $49,871

Yearly summary of insider trading at Ultragenyx Pharmaceutical Inc. (RARE) by Fust Matthew K

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2024 RARE 0 $0 12,195 $620,396 0 $0
2022 RARE 0 $0 0 $0 7,500 $302,775
2020 RARE 0 $0 14,931 $1,243,790 11,181 $234,801
2018 RARE 0 $0 6,319 $454,968 0 $0
2015 RARE 0 $0 0 $0 6,319 $132,699

Yearly summary of insider trading at Macrogenics Inc (MGNX) by Fust Matthew K

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2019 MGNX 0 $0 6,924 $203,427 6,924 $139,518

Yearly summary of insider trading at Atara Biotherapeutics, Inc. (ATRA) by Fust Matthew K

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2021 ATRA 0 $0 13,354 $260,403 0 $0
2018 ATRA 0 $0 12,286 $535,301 2,137 $0
2017 ATRA 0 $0 0 $0 6,410 $0
2016 ATRA 0 $0 0 $0 6,410 $0
2015 ATRA 0 $0 0 $0 10,683 $0


Insider trading activities at 6 companies by Fust Matthew K:

1. Neumora Therapeutics, Inc. (NMRA)

2. Crinetics Pharmaceuticals, Inc. (CRNX)

3. Dermira, Inc. (DERM)

4. Ultragenyx Pharmaceutical Inc. (RARE)

5. Macrogenics Inc (MGNX)

6. Atara Biotherapeutics, Inc. (ATRA)

Table 1. Insider trading of Neumora Therapeutics, Inc. (NMRA) by Fust Matthew K

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2024-10-17 NMRA Option Ex 7,739 6.54 50,636
2024-10-18 NMRA Option Ex 14,049 5.66 79,447
2024-10-17 NMRA Sale 7,739 17.01 131,640
2024-10-18 NMRA Sale 14,049 17.04 239,324

Table 2. Insider trading of Crinetics Pharmaceuticals, Inc. (CRNX) by Fust Matthew K

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2025-09-26 CRNX Option Ex 10,000 1.91 19,100
2025-09-26 CRNX Sale 16,000 44.75 716,000
2024-03-20 CRNX Sale 60,000 44.05 2,643,300
2024-03-20 CRNX Option Ex 60,000 21.25 1,274,880
2022-07-13 CRNX Sale 5,700 20.96 119,454
2022-07-13 CRNX Option Ex 5,700 1.45 8,265
2021-11-01 CRNX Option Ex 8,954 1.91 17,102
2021-11-01 CRNX Sale 8,954 25.50 228,327
2021-09-08 CRNX Option Ex 6,046 1.91 11,547
2021-09-08 CRNX Sale 6,046 25.50 154,173
2021-07-26 CRNX Option Ex 5,000 1.91 9,550
2021-07-26 CRNX Sale 5,000 19.59 97,950
2021-07-19 CRNX Sale 5,000 19.50 97,500
2021-07-19 CRNX Option Ex 5,000 1.91 9,550
2021-07-12 CRNX Sale 5,000 20.71 103,550
2021-07-12 CRNX Option Ex 5,000 1.91 9,550
2019-12-16 CRNX Option Ex 3,500 1.91 6,685
2019-12-16 CRNX Sale 3,500 22.50 78,750

Table 3. Insider trading of Dermira, Inc. (DERM) by Fust Matthew K

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2019-12-24 DERM Sale 3,000 15.00 45,000
2019-12-12 DERM Sale 3,000 12.00 36,000
2019-09-12 DERM Sale 6,000 8.77 52,638
2019-06-12 DERM Option Ex 3,000 .00 0
2018-10-19 DERM Sale 4,000 13.75 55,000
2018-06-13 DERM Option Ex 3,000 .00 0
2015-06-29 DERM Option Ex 9,051 5.51 49,871

Table 4. Insider trading of Ultragenyx Pharmaceutical Inc. (RARE) by Fust Matthew K

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2024-03-07 RARE Sale 12,195 50.87 620,396
2022-03-04 RARE Option Ex 7,500 40.37 302,775
2020-07-06 RARE Sale 6,181 90.00 556,290
2020-07-06 RARE Option Ex 6,181 21.00 129,801
2020-07-01 RARE Option Ex 5,000 21.00 105,000
2020-07-01 RARE Sale 5,000 85.00 425,000
2020-05-18 RARE Sale 1,875 75.00 140,625
2020-04-22 RARE Sale 1,875 65.00 121,875
2018-05-30 RARE Sale 6,319 72.00 454,968
2015-03-19 RARE Option Ex 6,319 21.00 132,699

Table 5. Insider trading of Macrogenics Inc (MGNX) by Fust Matthew K

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2019-02-06 MGNX Sale 6,924 29.38 203,427
2019-02-06 MGNX Option Ex 6,924 20.15 139,518

Table 6. Insider trading of Atara Biotherapeutics, Inc. (ATRA) by Fust Matthew K

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2021-11-04 ATRA Sale 13,354 19.50 260,403
2018-05-14 ATRA Sale 12,286 43.57 535,301
2018-05-15 ATRA Option Ex 534 .00 0
2018-02-15 ATRA Option Ex 1,603 .00 0
2017-11-15 ATRA Option Ex 1,602 .00 0
2017-08-15 ATRA Option Ex 1,603 .00 0
2017-05-15 ATRA Option Ex 1,602 .00 0
2017-02-15 ATRA Option Ex 1,603 .00 0
2016-11-15 ATRA Option Ex 1,602 .00 0
2016-08-15 ATRA Option Ex 1,603 .00 0
2016-05-16 ATRA Option Ex 1,602 .00 0
2016-02-16 ATRA Option Ex 1,603 .00 0
2015-11-16 ATRA Option Ex 1,602 .00 0
2015-08-17 ATRA Option Ex 1,603 .00 0
2015-05-15 ATRA Option Ex 7,478 .00 0

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Fust Matthew K (Director of Crinetics Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.